FDA scientists opposed Trump administration plan to ease peptide access
Health department proposal to loosen rules on unproven peptide drugs faced resistance from agency scientific staff.
At a glance
- FDA scientific staff opposed the proposal to loosen peptide drug regulations
- Scientists had limited input in drafting the policy
- The peptides are marketed for muscle building, injury healing and energy
- The proposal was posted online by the Department of Health and Human Services
A plan by the US Department of Health and Human Services to ease access to unproven peptide drugs encountered opposition from most Food and Drug Administration scientific staff members, according to sources familiar with the policy's development. The scientists had limited involvement in drafting the proposal, which was posted online and covers injectable peptides marketed in the wellness industry.
The peptides are promoted for muscle building, injury healing and energy enhancement. The effort was backed by the health secretary.
Why it matters
The disagreement highlights tensions between political leadership and scientific staff over drug safety standards and access to unproven treatments.
Original reporting
- The Guardian — WorldFDA scientists opposed Trump administration’s move to ease peptide access
This brief was written with AI assistance from the reports listed above and checked against our editorial policy. Spotted an error? Request a correction.
